



I hereby certify that the correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on October 2, 2003

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Examining Group 1632

Patent Application

Docket No. USF-T135

Serial No. 09/435,471

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner : Anne Marie Falk  
Art Unit : 1632  
Applicants : Denise R. Cooper, Niketa A. Patel  
Serial No. : 09/435,471  
Filed : November 8, 1999  
Conf. No. : 5279  
For : Glucose-Regulated mRNA Instability Element

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§1.97 AND 1.98**

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

10/10/2003 DENMANU1 00000060 190065 09435471

01 FC:1806 180.00 DA

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/435,471		
		Filing Date	November 8, 1999		
		First Named Inventor	Denise R. Cooper		
		Group Art Unit	1632		
		Examiner Name	Anne Marie Falk		
Sheet	1	of	1	Attorney Docket Number	USF-T135

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	PATEL, N.A. <i>et al.</i> "The protein kinase C $\beta$ II exon confers mRNA instability in the presence of high glucose concentrations" <i>J. Biol. Chem.</i> , 2003, 278(2):1149-1157.	
	R2	PATEL, N.A. <i>et al.</i> "Phosphoinositide 3-kinase mediates protein kinase C $\beta$ II mRNA destabilization in rat A10 smooth muscle cell cultures exposed to high glucose" <i>Arch. Biochem. Biophys.</i> , 2002, 403:111-120.	
	R3	YAMAMOTO, M. <i>et al.</i> "A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF-7 human breast cancer cells but not in multidrug resistant MCF-7/ADR cells which overproduce PKC- $\beta$ II" <i>Int. J. Cancer</i> , 1999, September, 83(1):98-106.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.